Combining Peptide Radiation Therapy with Chemotherapy Dramatically Improves Response in Aggressive Neuroendocrine Tumors
PRRT combined with capecitabine+temozolomide achieved a 71% response rate in FDG-positive neuroendocrine tumors, far exceeding PRRT alone (10%) or PRRT+temozolomide (14%).
Quick Facts
What This Study Found
PRRT + CAPTEM achieved 71% ORR and DCR in FDG-positive mNETs, compared to 10% ORR/50% DCR for PRRT alone and 14% ORR/43% DCR for PRRT + temozolomide, without increased toxicity.
Key Numbers
How They Did This
Retrospective single-center study of 24 FDG-positive mNET patients receiving PRRT alone (n=10), PRRT+TEM (n=7), or PRRT+CAPTEM (n=7), with response assessment by CT, Ga-68-DOTATOC PET, and FDG PET.
Why This Research Matters
FDG-positive neuroendocrine tumors have poor prognosis with standard PRRT. This combination approach could significantly improve outcomes for these aggressive cancers.
The Bigger Picture
This advances peptide-targeted radionuclide therapy by showing that combining it with chemotherapy can overcome the aggressive biology of FDG-positive neuroendocrine tumors.
What This Study Doesn't Tell Us
Small sample size (24 total, 7 per CAPTEM group). Retrospective design. Single center. Cannot control for selection bias between groups. Survival outcomes need longer follow-up.
Questions This Raises
- ?Would a prospective randomized trial confirm the superiority of PRRT+CAPTEM?
- ?Can the CAPTEM combination extend to other PRRT-treated tumor types?
- ?What is the optimal sequencing of PRRT and chemotherapy cycles?
Trust & Context
- Key Stat:
- 71% vs 10% response Adding CAPTEM chemotherapy to peptide radiation therapy dramatically improved response in aggressive neuroendocrine tumors
- Evidence Grade:
- Small retrospective single-center study. Dramatic response rate difference is noteworthy but needs prospective validation.
- Study Age:
- Published in 2025, addressing an unmet need in aggressive neuroendocrine tumor management.
- Original Title:
- Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.
- Published In:
- European journal of nuclear medicine and molecular imaging, 53(3), 1927-1938 (2026)
- Authors:
- di Santo, Gianpaolo(2), Santo, Giulia(2), Wirth, Lukas, Kronthaler, Ariane, Gastl, Günther, Djanani, Angela, Virgolini, Irene J
- Database ID:
- RPEP-15105
Evidence Hierarchy
Frequently Asked Questions
What is PRRT?
Peptide receptor radionuclide therapy uses radioactive peptides that bind to receptors on neuroendocrine tumor cells, delivering targeted radiation directly to the cancer while sparing healthy tissue.
Why combine PRRT with chemotherapy?
Some neuroendocrine tumors are too aggressive for PRRT alone. Adding chemotherapy (capecitabine and temozolomide) appears to dramatically improve response rates, with 71% of patients responding vs only 10% with PRRT alone.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15105APA
di Santo, Gianpaolo; Santo, Giulia; Wirth, Lukas; Kronthaler, Ariane; Gastl, Günther; Djanani, Angela; Virgolini, Irene J. (2026). Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.. European journal of nuclear medicine and molecular imaging, 53(3), 1927-1938. https://doi.org/10.1007/s00259-025-07606-3
MLA
di Santo, Gianpaolo, et al. "Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.." European journal of nuclear medicine and molecular imaging, 2026. https://doi.org/10.1007/s00259-025-07606-3
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor radionuclide therapy alone or in combinatio..." RPEP-15105. Retrieved from https://rethinkpeptides.com/research/di-2026-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.